PI3K, mTOR and NOTCH pathways are frequently dysregulated in T-cell acute lymphoblastic leukaemia (T-ALL). Blockade of PI3K and mTOR with the dual inhibitor PI-103 decreased proliferation in all 15 T-ALL cell lines tested, inducing cell death in three. Combined PI3K/mTOR/NOTCH inhibition (with a g-secretase inhibitor (GSI)) led to enhanced cell-cycle arrest and to subsequent cell death in 7/11 remaining NOTCH mutant cell lines. Commitment to cell death occurred within 48-72 h and was maximal when PI3K, mTOR and NOTCH activities were inhibited. PI-103 addition led to upregulation of c-MYC, which was blocked by coincubation with a GSI, indicating that PI3K/mTOR inhibition resulted in activation of the NOTCH-MYC pathway. Microarray studies showed a global increase in NOTCH target gene expression upon PI3K/mTOR inhibition. NOTCH-MYC-induced resistance to PI3K/mTOR inhibition was supported by synergistic cell death induction by PI-103 and a small molecule c-MYC inhibitor, and by reduction of the cytotoxic effect of PI-103 þ GSI by c-MYC overexpression. These results show that drugs targeting PI3K/mTOR can upregulate NOTCH-MYC activity, have implications for the use of PI3K inhibitors for the treatment of other malignancies with activated NOTCH, and provide a rational basis for the use of drug combinations that target both the pathways.
INTRODUCTION
The PI3K pathway is widely dysregulated in cancer and is a major focus for therapeutic intervention.
1 PI3K signalling can be enhanced by loss of function of the negative regulator, PTEN, leading to activation of the serine/threonine kinase, Akt. One of Akt's key targets is the mTOR pathway. mTOR belongs to a family of PI3K-related kinases and is a key regulator of cell growth and metabolism. It resides in two distinct signalling complexes, TORC1 and TORC2, 2 of which only TORC1 is sensitive to the actions of the drug rapamycin.
Owing to the widespread involvement of PI3K in cancer, novel agents have been developed that selectively target either individual class 1 PI3K isoforms, all class 1 isoforms, only mTOR, or both PI3K plus mTOR-some are in early phase clinical trials. [3] [4] [5] T-cell acute lymphoblastic leukaemia (T-ALL) constitutes about 15-25% of ALL cases and is molecularly heterogeneous. 6 Akt is frequently activated in T-ALL cells-this has been attributed to loss of PTEN function through deletion, mutation or microRNAinduced downregulation. [7] [8] [9] [10] [11] [12] [13] PTEN mutations and deletions are found in about 10-15% of cases at diagnosis. NOTCH pathway activation, which occurs at high frequency in T-ALL (see below), has also been reported to stimulate PI3K/mTOR activity. 8, 14 The NOTCH signalling pathway is critical for the controlled production of normal T cells, and ligand binding induces sequential cleavage of the NOTCH receptor, by ADAM-type metalloproteases and the g-secretase protease complex, resulting in release of active intracellular NOTCH (NICD). This translocates to the nucleus to control the transcription of target genes. NOTCH signalling is also regulated via its C-terminal PEST domain, which promotes proteasomal degradation by E3-ubiquitin ligase complexes containing the FBXW7 protein. 15 NOTCH1 is dysregulated in paediatric and adult patients with T-ALL at frequencies ranging from 31 to 76%, predominantly due to mutations in the heterodimerisation and PEST domains.
Inhibitor exposure T-ALL cell lines (0.5 Â 10 6 /ml) were incubated with inhibitors at the following concentrations, unless stated otherwise: 1 mM PI-103 (Selleck, Houston, TX, USA); 1 mM L-685,458 (Tocris Bioscience, Bristol, UK); 20 nM rapamycin (LC Laboratories, Woburn, MA, USA); 1 mM PIK90 (Merck, Darmstadt, Germany); 45 mM c-MYC Inhibitor 10058-F4 (Merck); 1 mM Bez-235 (LC Laboratories); 1 mM WYE-354; 1 mM KU-0063794; 1 mM PP242 (all Selleck).
Cell proliferation/viability assays T-ALL cells were refed and fresh inhibitors added on days 2 and 5. The number of viable cells and viability was determined by flow cytometry on days 0, 2, 5 and 7 using Annexin-V-FLUOS (Roche, Burgess Hill, UK)/ propidium iodide (PI)/flow-check fluorosphere (Beckman Coulter, High Wycombe, UK) profiling. The number of viable cells/ml was determined using the ratio of viable (Annexin-V negative PI negative ) cells to fluorospheres.
Washout experiments
Cells were exposed to control conditions or 1 mM PI-103 plus 1 mM L-685,458.
Control and treated cells were washed three times at 48, 72 and 120 h. At each time point those cells that had been exposed to inhibitors were halved between two flasks; one flask was exposed to control conditions and the other (continuous exposure) reexposed to inhibitors.
Cell-cycle analysis
Cells were pelleted and fixed overnight at À 20 1C in 70% methanol then stained in phosphate-buffered saline containing RNAse A (0.1 mg/ml), 0.05% Triton X-100 and 50 mg/ml PI for 40 min at 37 1C, washed and resuspended in phosphate-buffered saline for analysis of DNA content by flow cytometry.
Western blotting
Total cell lysates were prepared as described. 26 Nuclear and cytoplasmic lysates were prepared using the ProteoJet kit (Fermentas, St. Leon-Rot, Germany). Protein extracts were quantified (BIORAD, Hemel Hempstead, UK) and analysed by SDS-polyacrylamide gel electrophoresis and western blotting. Primary antibodies included: a-tubulin (Sigma, Gillingham, UK); cyclin D3, Cdk4, p27 Kip1 , histone H1 (Santa Cruz Biotechnology, Inc., Heidelberg, Germany); nuclear matrix protein 84 (AbCam, Cambridge, UK); Akt1, phospho-Akt (S473), phospho-Akt (Thr308), phospho-S6 ribosomal protein (Ser235/236), phospho-4E-BP1 (Thr37/46), c-MYC, cleaved NOTCH1 (Val1744)-NICD (Cell Signaling Technology, Danvers, MA, USA); and phospho-FKHRL1/Foxo3A (Thr32), PI3K p85 subunit (Millipore, Watford, UK).
Production of retrovirus, transduction and selection of SUP-T1 cells RD114 pseudotyped retroviral supernatants were generated by triple transfection of RDF (RD114 envelope), PeqPam (Moloney GagPol) and SFG-IRES-DCD34 or SFG-c-MYC-IRES-DCD34 (a kind gift from Brian Philip) vectors into 293T cells using Genejuice (Novagen, Darmstadt, Germany). Non-tissue culture plates were coated with Retronectin (TaKaRa Bio, Saint-Germain-en-Laye, France) and preloaded with viral supernatant for 30 min at room temperature. SUP-T1 cells and fresh viral supernatant were added followed by spinoculation at 1000 g for 50 min at room temperature. Transgene expression was determined by flow cytometry using anti-human-CD34-APC (BD Pharmingen, Oxford, UK). CD34-positive cells were positively isolated using MS columns (Miltenyi, Bisley, UK). Maintenance of transgene expression was determined before each experiment by flow cytometry.
RNA extraction for expression profiling RNA was extracted by lysis in TRIzol (Invitrogen, Paisley, UK) followed by capture, on-column DNAse treatment and purification using the PureLink RNA mini kit (Invitrogen). RNA was quantified and its purity evaluated using a Nanodrop spectrophotometer (Thermo Scientific, Southend, UK).
Gene expression profiling
RNA was extracted from DND41 cells, exposed to inhibitors for 72 h, as described above. Biological triplicates were prepared and RNA integrity was confirmed (Bioanalyser 2100 microfluidic system, Agilent Technologies, Wokingham, UK). Single-stranded DNA was produced from 1 mg of rRNA-reduced total RNA then fragmented and labelled using the GeneChip whole transcript (WT) sense target labelling WT kit (Affymetrix, High Wycombe, UK). Labelled single-stranded DNA was hybridised to Genechip Exon 1.0 arrays (Affymetrix). Raw signal intensities were background corrected and normalised using the robust multiarray average method of Irizarry et al. 27 Probe set log expression values were summarised to produce expression values for individual genes using the Genomics Suite software package (Partek, St. Louis, MO, USA), which was used to detect differentially expressed genes with associated fold changes and P-values using a two-way analysis of variance model. Gene-summarised expression values for a list of Notch target genes were input into GENE-E and gene set enrichment analysis software applications (Broad Institute) to produce heatmaps and enrichment plots, respectively. A Notch target gene list was compiled from published studies-to qualify, a gene had to be Notchregulated in at least two of five independent microarray studies. [28] [29] [30] [31] [32] Quantitative RT-PCR RNA was extracted from SUP-T1 and HPB-ALL cells, exposed to inhibitors as above. First strand cDNA was prepared using Superscript III reverse transcriptase (Invitrogen). Real-time quantitative PCR was performed using 100 ng of cDNA, 25 pmoles each of forward and reverse primers and 1 Â Power SYBR Green PCR mastermix (Applied Biosystems, Paisley, UK). Reactions were run on a Mastercycler ep realplex (Eppendorf, Stevenage, UK) using the following cycling parameters: 10 min at 95 1C followed by 45 cycles of 15 s at 95 1C, 30 s at 59-61.5 1C, 20 s at 68 1C. A melting curve was added to the end of the program to confirm specific amplification. Transcript expression was quantified using the standard curve method and NOTCH target expression normalised to the internal control TATA-binding protein (TBP). Primer Sequences were as follows:
CD21 Expression by flow cytometry
Cells were exposed to inhibitors for 48 h, then incubated with anti-human CD21-PE (Biolegend, Cambridge, UK) for 30 min at 4 1C, washed and analysed by flow cytometry.
RESULTS

Activation of NOTCH, PI3K and mTOR signalling in T-ALL cells
Constitutive activation of NOTCH signalling, as indicated by the presence of NICD, was present in the majority of cell lines, in keeping with their published mutational NOTCH1 status ( Figure 1a ). PI3K signalling, as judged by phosphorylation of Akt (at T308 and S473), was variably activated. Absolute correlation between loss of PTEN and constitutive PI3K activity, as previously suggested, 16 was not detected in our panel of cells-some PTENnegative cells showed no pAkt (MOLT-16) and some PTEN wildtype cells had high pAkt levels (SUP-T1 and HPB-ALL). In contrast, mTOR signalling, as determined by phosphorylation of ribosomal protein S6 (S6) and 4EBP1, was activated in all lines.
We examined the effect of blockade of either the NOTCH or the PI3K/mTOR pathway on relevant downstream signalling. Blockade of NOTCH by the GSI, L-685,458, resulted in decreased NICD in all cell lines that exhibited basal expression, regardless of their PTEN status (Figure 1b and unpublished data). Dual inhibition of PI3K/ mTOR signalling with PI-103 abrogated phosphorylation of both Akt and S6 (Figure 1c) . GSI attenuated the phosphorylation of the mTOR target S6 to a variable degree, but had no impact on Akt phosphorylation. The effect of NOTCH inhibition on mTOR activity has been previously described and may be c-MYC dependent. We compared the results obtained with PI-103 with NOTCH pathway blockade using the GSI L-685,458. Consistent with results from other groups, 16, 24, 25 GSI treatment had a modest and variable effect on cell proliferation, with only 5/13 cell lines with deregulated NOTCH showing a significant reduction in cell numbers (SUP-T1, DND41, HPB-ALL, TALL-1 and PEER) (Figures 2a and b) . SUP-T1 carries a NOTCH1 translocation but retains the g-secretase cleavage site, and DND41, HPB-ALL and PEER bear activating NOTCH1 mutations; TALL-1 does not carry a NOTCH1 mutation but has been shown in other studies to be sensitive to GSIs, 16, 33 indicating an as yet undiscovered mechanism of activation of this pathway.
The combination of PI3K/mTOR and NOTCH inhibition results in an enhanced anti-proliferative effect Although it has been postulated that PI3K activation can lie downstream of NOTCH signalling via suppression of PTEN expression, 8 the presence of coexisting genetic mutations in both NOTCH and PI3K pathways suggests that there is a growth and/or survival advantage to acquiring independent activation of each signalling module. Therefore, we investigated the effects of combined inhibition of PI3K/mTOR and NOTCH pathways. Figure 3a shows that in the majority of NOTCH mutant/PTENpositive cell lines (4/6), the combination of PI-103 and GSI resulted in a further reduction in proliferation, over and above that seen with PI-103 alone. In addition, the growth curves in some cell lines suggested that the combination of PI3K/mTOR and NOTCH blockade could be inducing cell death, as cell numbers fell below input values (for example, SUP-T1, DND41, HPB-ALL and TALL-1). In contrast, in PTEN-negative NOTCH mutant cells, only 1 of 7 cell lines (PF-382) showed a significant difference in the reduction in viable cell numbers seen for the combination of NOTCH plus PI3K/ mTOR inhibition over that seen with PI-103 alone (Figure 3b ).
To investigate further the effects of dual pathway blockade (PI3K/mTOR and NOTCH), we examined growth and cell-cycle regulation in those cell lines that were GSI sensitive. Blockade of either pathway resulted in decreased cell size, a phenomenon previously noted for NOTCH blockade 14, 29 and well-documented in other cell types for PI3K/mTOR inhibition 34 ( Figure 3c ). Previous studies in T-ALL have implicated a NOTCH-c-MYC-mTOR pathway for the effects of GSI on cell size.
14 If this were the sole mechanism by which NOTCH controls cell size, we would predict that adding GSI to a PI3K/mTOR inhibitor would not be additive as mTOR activity is already fully inhibited. However, the combination of PI-103 and GSI resulted in a further decrease in cell size compared with either agent alone, suggestive of at least partly nonoverlapping outputs (Figures 3c and d) .
Blocking both PI3K/mTOR and NOTCH activities resulted in a more rapid and profound cell-cycle arrest after 48 h treatment compared with either agent alone, with increased numbers of cells in G0/G1 (Figure 3e ). Mechanistically, dual pathway blockade was associated with marked reduction in levels of the cell-cycle regulators, cyclin D3 and CDK4 (Figure 3f ) both of which have been implicated as important factors in T-ALL proliferation. 33, 35 Cyclin D3 levels have previously been reported as being GSI sensitive 36 and we observed a similar finding in SUP-T1 cells, but not in HPB-ALL or DND41 cells. This variability may be due to differences in cell line models or cell culture conditions. The effects of dual blockade on the levels of the cell-cycle inhibitor p27 KIP1 were also variable in a cell line-dependent manner (Figure 3f ).
Inhibition of PI3K/mTOR leads to a NOTCH-dependent increase in c-MYC levels A significant body of evidence implicates c-MYC in the growth and proliferation of T-ALL cells. c-MYC is a direct transcriptional target of NOTCH signalling 14, 28, 29 and is also modulated at the posttranslational level through the PI3K/Akt/GSK3 signalling module. Phosphorylation and inactivation of GSK3 by Akt prevents GSK3-mediated phosphorylation and subsequent degradation of c-MYC protein. 37, 38 Therefore, inhibition of PI3K/Akt signalling would be predicted to increase c-MYC degradation and could contribute to the observed reduction in proliferation upon PI-103 treatment.
We measured c-MYC protein levels in those cell lines that were sensitive to inhibition of both pathways. Consistent with previous results, 14, 28, 29 inhibition of NOTCH signalling by GSI resulted in reduced c-MYC, indicating that in NOTCH-activated cells, this is the main driver of c-MYC expression (Figure 4a ). In contrast, and unexpectedly, we found that c-MYC levels were increased in the presence of PI-103 at 48 h of incubation (Figure 4a ). If cells were coincubated with PI-103 and GSI, this increase was abolished, indicating that the upregulation of c-MYC by PI3K/mTOR inhibition was NOTCH dependent (Figure 4a ). Time course experiments showed that PI3K/mTOR inhibition led to an early reduction in c-MYC protein and that the subsequent increase was associated with elevated nuclear levels of the active NICD (Figure 4b ).
Dual inhibition of NOTCH and PI3K/mTOR signalling induces cell death There is increasing evidence that targeted therapies that promote cell death, rather than just reducing proliferation, are more likely to produce clinical responses. 39, 40 Therefore, we formally investigated the effects of NOTCH and PI3K/mTOR inhibitors on cell survival using an Annexin V/PI flow cytometric assay. NOTCH inhibition with GSI did not induce significant levels of cell death in any of the cell lines (Figure 5a ). Only 3 of 15 cell lines (MOLT-16, KARPAS-45, MOLT-4) showed marked cell death in response to PI3K/mTOR inhibition alone (Figure 5b ). All these cell lines lack PTEN expression but six other cell lines without active PTEN did not show this effect. There was no direct correlation between pAkt levels ( Figure 1a ) and the induction of cell death in response to PI-103. When treated with combined NOTCH and PI3K/mTOR pathway inhibitors, 8/13 cell lines with activated NOTCH showed significant reduction in cell survival when compared with PI3K/mTOR inhibitors alone (Figure 5c ). Five of the six NOTCH1 mutant cell lines that retain normal PTEN expression responded to dual inhibition of PI3K/mTOR and NOTCH with cell survival of less than 50% at day 7 of treatment ( Figure 5c ). Owing to the strong correlation between PTEN mutation and GSI resistance, response to dual inhibition also correlated with GSI sensitivity. Dose-response assays showed cooperative and dose-dependent effects of PI-103 and GSI (Figure 5d ). Similar findings were obtained when combining an alternative GSI (Compound E) with PI-103, or an alternative PI3K/ mTOR inhibitor (Bez-235) with L-685,458 (data not shown).
Inhibition of both PI3K and mTOR is needed to produce maximal cytotoxicity in combination with GSI As PI-103 is a direct inhibitor of both PI3K and mTOR enzymes, we wished to investigate the effect of individual blockade of either pathway when combined with NOTCH inhibition. For these experiments, we utilised a selective PI3K inhibitor, PIK90 (which like PI-103 inhibits all class 1 PI3K isoforms), and the selective mTOR inhibitor, rapamycin. Figure 6a shows that the combination of either PIK90 or rapamycin with GSI was less effective than PI-103 plus GSI in inducing cell death in three different cell lines. If PIK90 and rapamycin were combined with GSI, the effect was of the same magnitude as PI-103 plus GSI. This suggests that effective blockade of both PI3K and mTOR is required to induce cell death to the levels seen when PI-103 is combined with NOTCH inhibition. As mTOR activation is frequently downstream of the PI3K/Akt pathway, it might have been predicted that a PI3K
inhibitor should have a similar biological effect to a PI3K/mTOR inhibitor. However, analysis of downstream signalling shows that, despite effective inhibition of PI3K/Akt by PIK90, there is residual mTOR activation as judged by phosphorylation of S6 (Figure 6b ). This indicates that in T-ALL, there are other inputs into the mTOR pathway, including NOTCH ( Figure 1c ) 14 and potentially the Ras/ MAPK pathway, as has been described for other tissues. 2 Recently, novel ATP-competitive TOR kinase inhibitors have been developed that inhibit both TORC1 and TORC2 complexes and are considered more potent inhibitors than rapamycin and its analogues. 41 Inhibition of TORC2 can diminish Akt activity by reducing phosphorylation of the serine 473 regulatory site. We directly compared the effects of novel TOR kinase inhibitors (WYE-654, KU-042, PP242) with PI-103 on T-ALL survival when combined with NOTCH blockade. Figure 6c shows that the combination of a TOR kinase inhibitor and GSI can also induce cell death but this is not as potent as that seen with PI-103. Combined PI3K/mTOR and NOTCH inhibition results in a rapid commitment to cell death Prolonged treatment with GSIs can result in significant toxicity, in particular to the gastrointestinal tract, thereby limiting their clinical application. 15 Time course experiments indicated that significant levels of cell death induced by PI3K/mTOR/NOTCH blockade were not detected until 5-7 days of incubation with inhibitors ( Figure 6d ). However, it is possible that cells may be irrevocably committed to cell death at earlier time points. To investigate this, we incubated T-ALL cells with PI-103 plus GSI for varying lengths of time, washed them extensively to remove the reversible compounds, and then replated them in fresh drug-free medium. Cell survival was then measured by Annexin V/PI flow cytometry at day 7 from the initiation of the experiment. Figure 6e shows that the majority of cells are committed to death within 2-3 days of drug exposure, when treated with the combination of NOTCH and PI3K/mTOR inhibitors. PI3K/mTOR inhibition results in a global increase in NOTCH signalling To examine if PI3K/mTOR inhibition has a specific effect on the NOTCH-MYC pathway or results in more global enhancement of NOTCH signalling, we carried out gene expression profiling by microarray analysis of DND41 cells treated with either PI-103, GSI or both inhibitors. Expression levels of a panel of previously welldefined NOTCH targets (including c-MYC, DTX1 and GIMAP5) [28] [29] [30] [31] [32] were assessed. Thirty-one of these genes were found to be GSI responsive in DND41 cells, the majority of which exhibited enhanced expression by PI-103 in comparison with control levels. The upregulation of these genes was NOTCH dependent, as it could be reversed by the addition of GSI (Figure 7a (Figures 7d and e) . Upregulation of CR2/CD21 was also achieved by incubation with the alternative PI3K/mTOR inhibitor Bez-235 (Figures 7f and g ). CR2/CD21 expression was also increased by the addition of the PI3K inhibitor PIK90, or more weakly by the mTOR inhibitor rapamycin and most strongly by the addition of both PIK90 and rapamycin, to a level near equivalent to PI-103 or Bez-235. (Figure 7f ). c-MYC is a key target in mediating resistance to PI3K/mTOR inhibitors To evaluate more specifically the role of c-MYC in mediating resistance to PI3K/mTOR blockade, we utilised the low molecular weight c-MYC inhibitor, 10058-F4, 42, 43 to determine whether combining this with PI-103 could enhance the effects of PI3K/ mTOR inhibition on cell survival, similar to the effects seen when combining PI-103 with GSI. Figure 8a shows that the c-MYC inhibitor increased cell death in a dose-dependent manner when combined with PI-103, at concentrations where the individual compounds have minimal effects on survival. This effect was consistently detected in a number of cell lines (Figure 8b ) and was reproduced with an alternative c-MYC inhibitor 10074-G5, which binds to a different region of c-MYC than 10058-F4 (ref. 44) (data not shown).
Next, we wanted to investigate whether maintaining c-MYC levels could counteract the effects of PI3K/mTOR/NOTCH blockade. We generated SUP-T1 cells that stably express c-MYC from a retroviral vector. Immunoblotting showed that transfected c-MYC levels were maintained in the presence of either GSI or PI-103 alone or both compounds together (Figure 8c ). Enforced expression of c-MYC in SUP-T1 cells partially prevented the induction of cell death in response to PI3K/mTOR/NOTCH blockade (Figure 8d ). 
DISCUSSION
In T-ALL, the PI3K/mTOR pathway, which is often deregulated, is a potential target for therapy. The most frequent abnormalities leading to PI3K/mTOR activation in T-ALL are found in PTEN 8, 11, 13, 45 Previous studies with PI3K, Akt and mTOR inhibitors suggested that these compounds are predominantly cytostatic, with relatively modest effects on cell death 37, 38, 46, 47 or utilised inhibitors such as LY294002 (ref. 10,48) known to have off-target effects on unrelated pro-survival kinases, including CK2 and PIM. 49 In addition to PI3K pathway abnormalities, the identification of NOTCH1 mutations in over half of T-ALL cases has identified this signalling pathway as a potential point for therapeutic intervention. However, laboratory studies have shown that GSIs that target this pathway have relatively modest effects on cell proliferation and fail to promote significant levels of cell death. 16, 24, 25 We show that dual inhibitors of PI3K/mTOR reduce cell growth in all T-ALL cells tested, regardless of whether or not they express functional PTEN. Of 15 cell lines tested, cell death was induced only in 3 PTEN-negative cell lines, suggesting that such cells may be more likely to be addicted to PI3K/mTOR signalling for cell survival. In the NOTCH1 mutant/PTEN wild-type category, which represents the bulk of patients with NOTCH mutations, PI3K/mTOR inhibition leads to feedback activation of the NOTCH pathway, providing a potential mechanism of resistance. We found increased levels of nuclear NOTCH in cells treated with PI-103 and this correlated with increased expression of a number of NOTCH targets including c-MYC. The relationship between NOTCH and PI3K signalling is not clear-cut. PI3K has been placed downstream of NOTCH via HES1-mediated inhibition of expression of PTEN expression. 8 Previous work has suggested both positive and negative interactions between the two pathways mediated by GSK3. [50] [51] [52] [53] Active forms of Akt have been reported to phosphorylate and inhibit NICD nuclear localisation 54 and it has been suggested that the PI3K-regulated kinase SGK can enhance FBXW7-mediated degradation of NICD; 55 therefore, blockade of PI3K signalling would be predicted to lead to increased levels of active NOTCH, as seen in our work.
We found that combined inhibition of NOTCH/PI3K/mTOR resulted in a more rapid and profound G0/G1 cell-cycle arrest compared with blockade of either pathway alone, with a marked decrease in cyclin D3 and CDK4 levels in cells with dual blockade. Previous work has shown the importance of cyclin D3, CDK4 and Rb in T-ALL pathophysiology. 33, 35 A key role for c-MYC in T-ALL pathophysiology has been postulated. [56] [57] [58] We show that the increased NOTCH signalling seen after PI3K/mTOR inhibition results in elevated c-MYC levels. c-MYC has recently been shown to confer resistance to the effects of PI3K/mTOR inhibition in mammary epithelial cells 59 and in a mouse model of breast cancer. 60 In T-ALL, downregulation of c-MYC using a small molecule inhibitor potentiated the effect of PI-103, resulting in marked cell death; conversely, the cytotoxic effects of PI-103 plus GSI were attenuated by c-MYC overexpression. Myc amplification resulting in resistance to PI3K inhibition can be an indirect effect due to selective evolutionary pressures-in T-ALL, the rapid upregulation of Myc protein (within 48 h) and its dependence on Notch signalling suggests a more direct effect of PI3K inhibition on this pathway. Further work will be required to elucidate the precise mechanisms underlying this phenomenon. A recent chemical-genetic screen in breast cancer cells has shown that ectopically induced NOTCH-MYC signalling can diminish the anti-proliferative effects of Bez-235, a dual PI3K/ mTOR inhibitor. 61 Our data show that in T-ALL cells with preexisting NOTCH pathway activation, PI3K/mTOR inhibition can of itself increase endogenous NOTCH-MYC signalling resulting in resistance. This can be overcome by blocking NOTCH or MYC signalling directly.
Previous clinical trials in T-ALL were halted due to lack of efficacy and marked GI toxicity. We show that a relatively brief exposure to combined NOTCH and PI3K/mTOR inhibition results in an irreversible commitment to cell death allowing for a truncated schedule that could diminish the risk of gastrointestinal toxicity and other side effects. Our results also show that for optimal induction of cell death, GSIs need to be combined with agents that block both PI3K and mTOR signalling. NOTCH1 mutations are also found in B-CLL, 62 and pathway activation is frequently seen in breast cancer, in some cases as a consequence of chromosomal translocation. 63 The PI3K pathway is also frequently activated in these malignancies. Our results have implications for the use of PI3K/mTOR inhibitors to treat patients with these tumours. However, there may be tissue-specific differences in regulatory signalling circuits and confirmatory studies will be required.
In summary, we have shown that there is an impaired cytotoxic response to PI3K/mTOR blockade in T-ALL due to compensatory upregulation of NOTCH-MYC signalling. This resistance can be overcome by combining PI3K/mTOR inhibitors with compounds that target either NOTCH or c-MYC. These results provide a scientific rationale for combining therapeutic agents that target these pathways for the treatment of T-ALL, and other malignancies where both NOTCH and PI3K pathways are dysregulated.
